Praxis’ epilepsy drug hits in phase 2, sparking stock rise and plans for next trial

Praxis Precision Medicines has recorded a midphase win in epilepsy, linking the high dose of PRAX-628 to a 100% complete response rate to clear the path for a larger study in the second half of the year.